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A B S T R A C T
Background: Multiple congenital defects are traditionally corrected surgically, but nowadays can be treated 
percutaneously. There are few reports in the literature attesting to its efficacy and safety. We aimed to 
describe an experience with combined procedures to treat different congenital and structural defects, in 
a single therapeutic session. 
Methods: Since 2007, different defects were treated in a single treatment session. All were selected by 
echocardiography. The procedures were performed using traditional techniques already described for each 
defect. 
Results: Ten patients were treated, five males, aged 1-67 years, weighting 11-90 kilograms. The most 
prevalent isolated defect was patent ductus arteriosus (PDA, n = 5), followed by ostium secundum atrial 
septal defects (osASD, n = 4) and ventricular septal defects (VSD, n = 4). The most common combinations 
were VSD with PDA (n = 2) and VSD with osASD (n = 2). Two pulmonary valve stenosis were dilated with 
osASD and patent foramen ovale (PFO), and one aortic coarctation with PDA. Additionally, a left atrial 
appendage with PFO was occluded and an aortopulmonary fistula with PDA was embolized. All procedures 
were successful. The mean follow-up was 31 ± 28.1 months, with only two complications. There were no 
deaths. 
Conclusions: The small number of reported cases showed that the combined procedures were safe and 
effective and can be reproduced by experienced operators in specialized centers and may be considered as 
the first therapeutic option in these patients.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. 
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
 
Procedimentos percutâneos combinados em defeitos estruturais e congênitos
R E S U M O
Introdução: Defeitos congênitos múltiplos são tradicionalmente corrigidos cirurgicamente, mas, 
atualmente, podem ser tratados percutaneamente. Existem poucos relatos na literatura atestando 
sua eficácia e segurança. Objetivamos descrever uma experiência com a realização de procedimentos 
combinados para tratar diferentes defeitos, congênitos e estruturais, numa mesma sessão terapêutica.
Métodos: Desde 2007, foram tratados, numa mesma sessão terapêutica, diferentes defeitos. Todos foram 
selecionados por ecocardiograma. Os procedimentos foram realizados segundo as técnicas tradicionais já 
descritas para cada defeito encontrado.
Resultados: Foram tratados dez pacientes, cinco do sexo masculino, com idades de 1 a 67 anos, e pesos de 11 
a 90 kg. O defeito mais prevalente de forma isolada foi a persistência do canal arterial (PCA, n = 5), seguido 
da comunicação interatrial ostium secundum (CIA OS, n = 4) e da comunicação interventricular (CIV, n = 4). 
As combinações mais frequentes foram CIV com PCA (n = 2) e CIV com CIA OS (n = 2). Foram dilatadas duas 
estenoses valvares pulmonares, com CIA OS e com forame oval patente (FOP), e uma coarctação de aorta 
com PCA. Adicionalmente, foi ocluído um apêndice atrial esquerdo com FOP e foi embolizada uma fístula 
aortopulmonar com PCA. Todos os procedimentos foram bem-sucedidos. O tempo médio de seguimento foi 
de 31 ± 28,1 meses, havendo apenas duas complicações. Não houve nenhum óbito.
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Introduction
Percutaneous intervention is currently the therapeutic modality 
of choice for most simple congenital heart diseases, as well as for 
some structural defects, with similar results and sometimes even 
advantage over conventional surgery.1,2
Multiple congenital defects are traditionally corrected through 
surgical techniques. Although the feasibility of percutaneous inter-
vention for different defects in the same procedure has been de-
scribed in some case reports, its efficacy and safety have not been 
consistently evaluated.3-6
In this article, the authors analyze their experience with com-
bined procedures performed for treatment of different defects, both 
congenital and structural, and discuss technical aspects and indica-
tions. Finally, some comments are offered on the effectiveness and 
safety of the procedures performed.
Methods
The medical records of all patients who underwent percutaneous 
procedures to treat various heart defects in a single therapeutic 
session were retrospectively analyzed. Cases of more than one de-
vice implanted for treating the same type of anatomical defect and 
cases in which an atrial septal defect and patent foramen ovale (PFO) 
were occluded during the same procedure were excluded from this 
analysis.
Procedures
All procedures were performed under general anesthesia and 
orotracheal intubation after at least an 8 hour fasting. The patients 
underwent right and left heart catheterization by femoral puncture. 
Relevant angiograms were performed in each case.
Heparin was administered at doses of 100 IU/kg in children and of 
5,000-10,000 IU in adults after a venous access was obtained and a 
transesophageal sheath was introduced. Antimicrobial prophylaxis 
with cefazolin (50 mg/kg in children or 2 g in adults) was routinely 
administered.
As a general rule, procedures regarded as more complex, time-
consuming, or laborious were performed first, followed by those 
considered simpler or technically less demanding. In the case of 
association with valvar stenosis, these conditions were addressed 
first.
All occlusive procedures and all dilations were performed 
according to standard techniques, detailed elsewhere.2,7-11 Occlusive 
procedures were monitored by transesophageal echocardiography 
(TEE), in addition to fluoroscopy.
All patients were followed-up in the intensive care unit after the 
procedure and were discharged after undergoing a control transtho-
racic echocardiography (TTE) 24 hours after the index procedure.
Follow-up
Patients undergoing ostium secundum atrial septal defect 
(osASD), PFO, ventricular septal defect (VSD), and left atrial append-
age (LAA) occlusions were instructed to use acetylsalicylic acid (3-5 
mg/kg/day in children or 200 mg/day in adults) for 6 months, in ad-
dition to 75 mg of clopidogrel bisulfate in adults for 3 months in 
cases with this indication. In patients whose procedure involved 
only stenting, antiplatelet therapy with acetylsalicylic acid was rec-
ommended for 6 months. All patients were instructed to observe the 
prophylactic recommendations for infective endocarditis for a peri-
od of 6 months, when necessary.
Clinical follow-up was performed at 1, 3, 6, and 12 months after 
the procedure, and annually thereafter. Image monitoring with TTE 
was performed in visits at 1, 3, and 12 months, and annually thereaf-
ter; at the 6 month visit, TEE was performed for evaluation of the 
procedure outcome.
In addition to clinical examinations and routine echocardio-
grams, stents were angiographically evaluated after 6 months.
Results
Since 2007, 982 patients were submitted to interventional pro-
cedures; in 10 patients (1.0%), two different defects were treated in 
the same session. Five patients were male, with age ranging from 1 
to 67 years (14 ± 24.3 years), and with weight ranging from 11 to 90 
kg (50 ± 26.9 kg).
Table 1 shows demographic data of these ten patients included 
in this study, as well as combinations of the structural defects 
treated. Globally, 20 congenital and structural defects were treat-
ed, with patent ductus arteriosus (PDA) the most prevalent (n = 5) 
in isolation, followed by osASD (n = 4) and VSD (n = 4). The most 
common combinations were VSD with PDA (n = 2) and VSD with 
osASD (n = 2).
Of the 20 procedures performed in these ten patients, a combina-
tion of two procedures of occlusion was performed in the majority of 
cases (n = 7). In two cases, balloon pulmonary valvuloplasty (BPV) 
was performed in combination with PFO (n = 1) and osASD (n = 1) 
occlusion. In another patient with aortic coarctation (AoC) and PDA, 
AoC was treated with balloon dilation and with the implantation of 
a polytetrafluoroethylene (PTFE)-coated stent, positioned so as to 
also occlude the ductus arteriosus origin. A variety of devices with 
different characteristics and from different suppliers were used to 
conduct these procedures (Table 2).
Table 1
Demographics and structural defects.
Nº ID Gender
Age 
(years)
Weight 
(kg) Defects
1 JAA M 57 90 PVS + PFO 
2 GCO M 1 11 PDA + aortopulmonary collaterals
3 BMOA F 14 50 Perimembranous VSD + osASD
4 LCMM F 35 59 Multiple muscular VSDs + PDA
5 GOR F 29 56 PDA + osASD
6 JKVSG M 3 14 PVS + osASD
7 JMFV M 4 15 Perimembranous VSD + PDA
8 SMGQ F 67 65 Chronic AF with stroke + PFO
9 GGR M 10 42 Perimembranous VSD + osASD
10 IVM F 7 24 AoC + PDA
ID: patient identification; M: male; PVS: pulmonary valve stenosis; PFO: patent foramen ovale; PDA: 
patent ductus arteriosus; F: female; VSD: ventricular septal defect; osASD: ostium secundum atrial 
septal defect; AF: atrial fibrillation; AoC: aortic coarctation.
Conclusões: A pequena série de casos relatada mostrou que os procedimentos combinados foram seguros e 
eficazes, podendo ser reproduzidos por operadores experientes em centros especializados, podendo vir a 
se constituir como primeira opção terapêutica para esses pacientes.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
 F. Chamié et al. / Rev Bras Cardiol Invasiva. 2015;23(1):61-65 63
Procedural characteristics
Pulmonary balloon valvuloplasty
Pulmonary balloon valvuloplasty (PBV) was performed as first 
procedure in two cases. The pulmonary transvalvar gradients were 
40 mmHg and 60 mmHg, and reduced for 8 mmHg and 28 mmHg, 
respectively, after dilation.
In Case 1, an adult patient, the double-balloon technique was 
used on a single guidewire (MULTI-TRACKTM system – Numed, Hop-
kinton, USA), with two 14/40 mm balloons, with good results (Fig. 1). 
In Case 6, a 3-year-old child, a 16 mm OsypkaTM Vacs II balloon was 
used (Osypka AG – Rheinfelden-Herten, Germany). In both cases, the 
valve lesion was approached first; then, septal occlusion was per-
formed with a 25 mm AmplatzerTM PFO occluder (St. Jude Medical – 
St. Paul, USA) (Case 1) and with a 22 mm PFM ASD-R 22 mm occluder 
(PFM AG, Köln, Germany) (Case 6). Both patients recovered unevent-
fully.
Patent ductus arteriosus occlusion
Arterial ducts were occluded as a first procedure in three cases 
(Cases 2, 4, and 5) through the traditional technique with the use of 
a 6/4 mm AmplatzerTM Duct Occluder type I (St. Jude Medical – St. 
Paul, USA) and of a 16 mm Muscular VSD CeraTM Occluder and a 6/8 
mm CeraTM PDA Occluder (Lifetech – Shenzhen, China). In Case 2, the 
occlusion of a collateral vessel was performed as a second proce-
dure, using two FlipperTM 3PDA3 springs (Cook Medical – Blooming-
ton, USA) released sequentially. In Case 4, two muscular VCDs were 
occluded (described below). In Case 5, one osASD was also occluded 
with an 18 mm CeraTM ASD Occluder (Lifetech – Shenzhen, China). 
Both patients had a successful outcome, with no case of descending 
aorta or pulmonary left branch obstruction (Fig. 2).
Perimembranous ventricular septal defect occlusion
Perimembranous VSD occlusion was performed as the first proce-
dure in three cases. All patients had a normal pulmonary systolic 
pressure and some degree of increase in their left ventricular diastol-
ic diameters by volume overload. No case exhibited aortic regurgita-
tion before or after the procedure. In Case 3, the VSD was a 
consequence of a postoperative residual hole caused by surgical patch 
dehiscence, and the other two were birth defects (Cases 7 and 9). The 
defects measured, respectively, 7 mm, 5 mm, and 8 mm at the right 
ventricular side. These defects were sealed with CeraTM VSD type I Oc-
cluders (8 mm, 7 mm, and 10 mm). In the same procedure, two osASD 
(Cases 3 and 9) and one PDA (Case 7) were also occluded. The osASD 
cases were occluded as a second procedure with the use of a 16 mm 
CeraTM ASD Occluder and a 22 mm CeraTM Flex ASD Occluder. PDA was 
closed with a 6/8 mm CeraTM PDA Flex Occluder device.
In case 9, after osASD occlusion, it was observed that the VSD 
prosthesis had embolized into the left pulmonary artery branch. The 
device was then captured with a 20 mm loop catheter and removed 
through the 12 mm long sheath used to implant the osASD prosthe-
sis. At the end of the procedure, both defects were occluded, and the 
intervention was finished without further complications (Fig. 3).
In none of the cases treated was there interference in the tricuspid 
valve; in addition, there was no aortic regurgitation. After the proce-
dure, there were no disturbances in atrioventricular conduction.
Membranous ventricular septal defect occlusion
Case 4, a woman, exhibited severe pulmonary hypertension re-
sulting from multiple muscular VSDs. During routine catheteriza-
tion, a 10 mm tubular PDA not diagnosed by transthoracic 
echocardiography was noted. This defect was occluded as a first 
Table 2
Procedures completed and prostheses used.
N ID Procedures Prostheses
1 JAA PBV + PFO occlusion MULTI-TRACKTM system 14/40 + 
AmplatzerTM PFO Occluder 25 mm
2 GCO PDA occlusion + 
aortopulmonary collateral 
embolization
AmplatzerTM Duct Occluder 1, 6-4 mm 
+ FlipperTM Coils 3PDA3
3 BMOA Perimembranous VSD 
occlusion + osASD occlusion
CeraTM VSD Occluder type 18 mm + 
CeraTM ASD Occluder 16 mm
4 LCMM Muscle VSD occlusion + PDA 
occlusion
CeraTM VSD Muscle Occluder 10 and  
14 mm + CeraTM VSD Muscle Occluder 
16 mm
5 GOR PDA occlusion + osASD 
occlusion
CeraTM PDA Occluder 8/6 mm + CeraTM 
ASD Occluder 18 mm
6 JKVSG PBV + osASD occlusion OsypkaTM Vacs II balloon 16/30 mm + 
PFM ASD-R 24 mm
7 JMFV Perimembranous VSD 
occlusion + PDA occlusion
CeraTM VSD Occluder type 1, 7 mm + 
CeraTM PDA Occluder Flex 8/6 mm
8 SMGQ AAE occlusion + PFO 
occlusion
AmplatzerTM Cardiac Plug 24 mm + 
AmplatzerTM PFO Occluder 25 mm
9 GGR Perimembranous VSD 
occlusion + osASD occlusion
CeraTM VSD Occluder type 1, 14 mm + 
CeraTM ASD Occluder Flex 22 mm
10 IVM AoC dilation + stenting Power Flex Plus 12/40 mm balloon + 
8ZIG28 CP-coated stent 
ID: patient identification; PBV: pulmonary balloon valvuloplasty; PFO: patent foramen ovale; PDA: 
patent ductus arteriosus; VSD: ventricular septal defect; osASD: ostium secundum atrial septal de-
fect; LAA: left atrial appendage; AoC: aortic coarctation.
Figure 1. Pulmonary valve dilation with MULTI-TRACKTM System. An indentation in the 
lower third of the two balloons is noted, corresponding to the plane of the pulmonary 
valve. Notice the two balloons introduced on a single guide-wire.
Figure 2. In A, aortography in the left view. The tubular ductus arteriosus, measuring 
10 mm, can be seen. In B, occlusion with CeraTM prosthesis for muscular VSD is ob-
served.
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procedure, with a 16 mm muscular VSD CeraTM Occluder device. In 
continuation, two muscular VSDs with 8 and 11 mm were occluded 
with 10 mm and 14 mm Muscular VSD CeraTM Occluder prostheses. 
At the end of the procedure, no significant reduction in pulmonary 
pressure was noted, and the woman remained in outpatient treat-
ment, following a specific protocol for pulmonary arterial hyper-
tension.
Dilation of aortic coarctation
Case 10, a 7-year-old child, had AoC and a conical PDA. This 
patient had the AoC dilated and the PDA occluded simultaneously 
by stenting with a CP Coated 8ZIG28 device, mounted on a Power 
Flex Plus 12/40 mm balloon introduced through a Mullins 10 F 
sheath over a rigid guidewire positioned into the left subclavian 
artery. The gradient through the narrowed area was 64 mmHg 
and, after stenting, fell to 5 mmHg. The procedure was successful 
and both lesions were treated properly without complications 
(Fig. 4).
Left atrial appendage occlusion
Case 8, a 67-year old woman with chronic coronary artery dis-
ease, suffered two myocardial infarctions at the ages of 32 and 33, 
having undergone coronary artery bypass grafting in 1983 and 
2000. Since 2013, this patient had atrial fibrillation. In May 2014, the 
woman suffered an ischemic stroke, when PFO was diagnosed by 
TEE. Oral anticoagulation was introduced with warfarin and discon-
tinued for retinal hemorrhage. The LAA was accessed through the 
foramen ovale, with no need for a transeptal puncture, and the de-
fect was closed with a 24 mm AmplatzerTM Cardiac Plug prosthesis. 
Her PFO was closed with a 25 mm AmplatzerTM PFO Occluder, using 
the same cable and delivery sheath. Both defects were successfully 
closed (Fig. 5).
Follow-up
The mean time of follow-up was 31 ± 28.1 months (1-84 months).
There were no residual shunts in cases of aortopulmonary col-
laterals, PDA, osASD, PFO, perimembranous VSD, and LAA occlu-
sions. In Case 4, a small residual shunt remained in the upper portion 
of the second muscular VSD prosthesis implanted.
In Case 10, no significant residual gradient in AoC was noted.
Two minor complications were noted: embolization of a muscu-
lar VSD prosthesis (Case 9), which was removed without difficulty 
from the left pulmonary artery branch, and a small arteriovenous 
Figure 5. The picture shows the presence of the AmplatzerTM Cardiac Plug into the left 
atrial appendage, in the uppermost position; and, more inferiorly, the AmplatzerTM 
PFO Occluder device occluding the foramen ovale. The long sheath with double curva-
ture and the delivery cable inwardly can also be seen, immediately after the release of 
the second prosthesis.
Figure 4. In A, the aortography in the left view shows the presence of aortic coarctation. Note that there is also a conical ductus arteriosus, opacifying the pulmonary trunk. In B, 
in the same view, the coated stent positioned through the coarctation can be seen, already outside and above the delivery sheath. In C, the fully expanded stent, promoting co-
arctation dilation, and a complete occlusion of the ductus arteriosus are observed.
BA C
Figure 3. In A, left ventriculography in a long-axis left anterior oblique view shows 
VSD below the aortic valve. In B, VSD was occluded by a type-I VSD CeraTM Occluder. 
In C, the presence of a CeraTM ASD Flex Occluder device can be seen occluding the os-
tium secundum atrial septal defect and the device in the ventricular septal defect 
embolized into the left pulmonary artery branch. Note that the connecting pin is cap-
tured by the loop catheter. In D, the VSD prosthesis is being removed through the long 
sheath. In E, ASD device in position and the second VSD prosthesis completely closing 
the defect can be seen.
 F. Chamié et al. / Rev Bras Cardiol Invasiva. 2015;23(1):61-65 65
fistula at the puncture site (Case 8), which was repaired by surgical 
suture; this complication was probably caused by an arterial injury 
provoked during previous coronary angiograms. There were no 
deaths in this small series.
Discussion
The repair of more than one heart defect has been traditionally 
performed by surgery. The development of percutaneous therapeu-
tic techniques allowed for an approach for most of the simpler car-
diac defects and, in some cases, became the treatment of choice for 
the aforementioned defects in centers with specialized profession-
als.3-6,12-16
The accomplishment of combined procedures is not a simple task 
and demands careful planning. Some basic principles should be fol-
lowed with the utmost accuracy: in a patient with a combination of 
heart defects, it is essential that all of them can be addressed percu-
taneously through established techniques, and with universally 
proven results. Otherwise, the patient should be referred for surgical 
correction, which will promote a full and proper resolution of the 
defects found.
Similarly, it is not good practice to treat a defect percutane-
ously before all possibilities of spontaneous resolution have been 
exhausted.
With respect to technical aspects, most authors guide their pro-
cedures based on dogmas; for instance, addressing valvar lesions 
first,12 i.e., approaching the most difficult or more complex defect 
first and then the simpler or less complicated condition,14 and con-
sidering the feasibility of access to defects. The more remote defects 
should be tackled first. Thus, a septal defect should not be occluded 
first, knowing that the left atrium must be accessed in order to treat 
the atrial appendage or the mitral valve subsequently.
In the procedures presented in this study, it was attempted to 
follow the above considerations. However, the approach sequence 
was reversed in two cases without jeopardizing the outcomes. In 
Case 4, the patient’s ductus arteriosus was closed before the mus-
cular VSDs, which caused no difficulty whatsoever for the occlusion 
of the ventricular septal defects. In Case 9, the perimembranous 
VSD was closed first, followed by osASD closure, as recommended. 
After the release of the osASD device, an embolization of the VSD 
prosthesis was noted; thus, the prosthesis was removed. Then, an 
equivalent prosthesis was implanted into the ventricular septum, 
but this new device was of a larger size than the previous prosthe-
sis, and there was no interference or difficulty caused by the pres-
ence of a prosthesis in the atrial septum. As a general rule, the 
guidance listed herein is quite adequate, but there may be room for 
improvisations at the discretion of physician experience, provided 
they do not hinder nor jeopardize the full resolution of the defects 
in question.
The advantages of a simultaneous treatment of combined defects 
are quite obvious. Besides offering an alternative treatment for pa-
tients traditionally addressed surgically, with all its inherent risks 
and drawbacks, this alternative prevents the occurrence of multiple 
interventional procedures, minimizes radiological exposure, pre-
vents the risk of repeated anesthetic procedures, reduces the num-
ber of vascular punctures, and cuts costs.
Conclusions
In this small study, all procedures performed have proven to be 
safe, effective, and potentially reproducible by experienced physi-
cians. In the present state of interventional cardiology, the completion 
of concomitant procedures in combined defects is a reality, which can 
represent the first therapeutic choice in specialized centers.
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